Cargando…
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
BACKGROUND: To date, this is the only report showing with close and consecutive magnetic resonance images the extremely rapid response of two types of pediatric low-grade gliomas (PLGG) to vemurafenib and its impact on the surgical approach. CASES PRESENTATION: We report two cases of symptomatic PLG...
Autores principales: | Piccolo, Gianluca, Verrico, Antonio, Morana, Giovanni, Piatelli, Gianluca, De Marco, Patrizia, Iurilli, Valentina, Antonelli, Manila, Gaggero, Gabriele, Ramaglia, Antonia, Crocco, Marco, Caruggi, Samuele, Milanaccio, Claudia, Garrè, Maria Luisa, Pavanello, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706968/ https://www.ncbi.nlm.nih.gov/pubmed/36447197 http://dx.doi.org/10.1186/s12887-022-03711-6 |
Ejemplares similares
-
SURG-07. The impact of early targeted therapy on the neurosurgical approach to pediatric low-grade glioma
por: Piatelli, Gianluca, et al.
Publicado: (2022) -
LGG-34. Nephrological impact of BRAF inhibitors in a pediatric population of central nervous system tumors: a single institution experience
por: Verrico, Antonio, et al.
Publicado: (2022) -
LGG-35. Dyslipidemia in children treated with BRAF inhibitors for brain tumor, a new side effect? A single center retrospective study
por: Crocco, Marco, et al.
Publicado: (2022) -
Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?
por: Crocco, Marco, et al.
Publicado: (2022) -
LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma
por: Verrico, Antonio, et al.
Publicado: (2022)